Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Cellular Cytotoxicity of Next Generation CD20 Monoclonal Antibodies.

VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS.

Cancer Immunol Res. 2018 Aug 8. pii: canimm.0319.2018. doi: 10.1158/2326-6066.CIR-18-0319. [Epub ahead of print]

PMID:
30089638
2.

Management of melanoma in patients with chronic lymphocytic leukemia.

Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS.

Leuk Res. 2018 Aug;71:43-46. doi: 10.1016/j.leukres.2018.07.003. Epub 2018 Jul 6.

PMID:
30005183
3.

Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Jun 7. pii: haematol.2018.193615. doi: 10.3324/haematol.2018.193615. [Epub ahead of print]

4.

Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS.

Leuk Lymphoma. 2018 Mar;59(3):625-632. doi: 10.1080/10428194.2017.1347931. Epub 2017 Jul 11.

PMID:
28696801
5.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

6.

Ibrutinib therapy for lymphoplasmacytic lymphoma.

Helber MJ, Moore JE, Williams AM, Meacham PJ, Rothberg PG, Zent CS.

Am J Hematol. 2017 Sep;92(9):E542-E544. doi: 10.1002/ajh.24795. Epub 2017 Jun 9. No abstract available.

PMID:
28543765
7.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

PMID:
28453705
8.

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR.

Leukemia. 2017 Jun;31(6):1348-1354. doi: 10.1038/leu.2017.34. Epub 2017 Jan 24.

9.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

10.

Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.

Zent CS, Elliott MR.

FEBS J. 2017 Apr;284(7):1021-1039. doi: 10.1111/febs.13961. Epub 2016 Nov 29. Review.

11.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

12.

CLL: an acquired immunodeficiency disease.

Zent CS.

Blood. 2016 Oct 13;128(15):1908-1909. No abstract available.

13.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

14.

What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Williams AM, Zent CS, Janelsins MC.

Br J Haematol. 2016 Sep;174(6):835-46. doi: 10.1111/bjh.14211. Epub 2016 Jul 8. Review.

15.

Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation.

Zent CS.

Leuk Lymphoma. 2016 May;57(5):985-6. doi: 10.3109/10428194.2015.1121263. Epub 2016 Jan 4. No abstract available.

PMID:
26726799
16.

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.

Zent CS, Bowen DA, Conte MJ, LaPlant BR, Call TG.

Leuk Lymphoma. 2016 Jul;57(7):1585-91. doi: 10.3109/10428194.2015.1113280. Epub 2015 Dec 24.

PMID:
26699397
17.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
18.

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS.

Am J Hematol. 2016 Mar;91(3):308-12. doi: 10.1002/ajh.24265. Epub 2016 Feb 9.

19.

Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.

Church AK, VanDerMeid KR, Baig NA, Baran AM, Witzig TE, Nowakowski GS, Zent CS.

Clin Exp Immunol. 2016 Jan;183(1):90-101. doi: 10.1111/cei.12697. Epub 2015 Oct 28.

20.

Management of chronic lymphocytic leukemia.

Stilgenbauer S, Furman RR, Zent CS.

Am Soc Clin Oncol Educ Book. 2015:164-75. doi: 10.14694/EdBook_AM.2015.35.164. Review.

21.

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.

Zent CS, Burack WR.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):119-24. doi: 10.1182/asheducation-2014.1.119. Epub 2014 Nov 18. Review.

PMID:
25696844
22.

Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.

Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ.

Leuk Lymphoma. 2015;56(8):2373-8. doi: 10.3109/10428194.2015.1016932. Epub 2015 Mar 17.

23.

Infection in chronic lymphocytic leukemia: parsimony has its limits.

Barr PM, Zent CS.

Leuk Lymphoma. 2014 Dec;55(12):2683-4. doi: 10.3109/10428194.2014.917642. Epub 2014 May 16. No abstract available.

PMID:
24766466
24.

Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication.

Bowen DA, Rabe KG, Schwager SM, Slager SL, Call TG, Viswanatha DS, Zent CS.

Leuk Lymphoma. 2015 Feb;56(2):311-4. doi: 10.3109/10428194.2014.914202. Epub 2014 Jun 25.

PMID:
24738974
25.

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE.

Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26.

26.

Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.

Call TG, Norman AD, Hanson CA, Achenbach SJ, Kay NE, Zent CS, Ding W, Cerhan JR, Rabe KG, Vachon CM, Hallberg EJ, Shanafelt TD, Slager SL.

Cancer. 2014 Jul 1;120(13):2000-5. doi: 10.1002/cncr.28690. Epub 2014 Apr 7.

27.

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, Zent CS.

J Immunol. 2014 Feb 15;192(4):1620-9. doi: 10.4049/jimmunol.1302954. Epub 2014 Jan 15.

28.

Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, Call TG, Viswanatha DS, Zent CS.

Leuk Lymphoma. 2014 Sep;55(9):2079-84. doi: 10.3109/10428194.2013.869801. Epub 2014 Feb 17.

29.

The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management.

Barr PM, Zent CS.

Leuk Lymphoma. 2014 Jun;55(6):1219-20. doi: 10.3109/10428194.2013.844343. Epub 2013 Nov 1. No abstract available.

PMID:
24047480
30.

Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.

Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, Zent CS.

Br J Haematol. 2013 Nov;163(3):326-33. doi: 10.1111/bjh.12534. Epub 2013 Aug 27.

31.

Genetic risk of chronic lymphocytic leukemia: a tale of two cities.

Slager SL, Zent CS.

Leuk Lymphoma. 2014 Apr;55(4):735-6. doi: 10.3109/10428194.2013.840889. Epub 2013 Nov 1. No abstract available.

PMID:
24015842
32.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.

Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text.

33.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD.

Br J Haematol. 2013 Sep;162(6):774-82. doi: 10.1111/bjh.12458. Epub 2013 Jul 11.

34.

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.

Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR.

Cancer Immunol Immunother. 2013 Sep;62(9):1475-84. doi: 10.1007/s00262-013-1452-4. Epub 2013 Jun 28.

35.

Visual loss in early-stage chronic lymphocytic leukemia.

Gonsalves WI, Zent CS, Pulido JS, Patnaik MM.

J Clin Oncol. 2013 Jun 10;31(17):e280-2. doi: 10.1200/JCO.2012.46.7431. Epub 2013 May 6. No abstract available.

PMID:
23650405
36.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ.

Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.

37.

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE.

Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14.

38.

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Lindorfer MA, Wiestner A, Zent CS, Taylor RP.

Oncoimmunology. 2012 Sep 1;1(6):959-961.

39.

Anti-CD20 antibody therapy for B-cell lymphomas.

Taylor RP, Lindorfer MA, Zent CS.

N Engl J Med. 2012 Aug 30;367(9):876-7; author reply 878. doi: 10.1056/NEJMc1207378. No abstract available.

PMID:
22931338
40.

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, Kay NE, Leis JF, Call TG.

Leuk Lymphoma. 2013 Mar;54(3):476-82. doi: 10.3109/10428194.2012.717276. Epub 2012 Aug 22.

41.

Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE.

Cancer. 2013 Jan 15;119(2):363-70. doi: 10.1002/cncr.27719. Epub 2012 Jul 3.

42.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.

Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR.

Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.

43.

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS.

Leuk Lymphoma. 2012 Nov;53(11):2218-27. doi: 10.3109/10428194.2012.681657. Epub 2012 May 21.

44.

Improving quality of life in chronic lymphocytic leukemia.

Zent CS.

Leuk Lymphoma. 2012 Jul;53(7):1247-8. doi: 10.3109/10428194.2012.656106. Epub 2012 Feb 13. No abstract available.

PMID:
22242823
45.

Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

Gustafson MP, Abraham RS, Lin Y, Wu W, Gastineau DA, Zent CS, Dietz AB.

Br J Haematol. 2012 Mar;156(5):674-6. doi: 10.1111/j.1365-2141.2011.08902.x. Epub 2011 Nov 3. No abstract available.

46.

Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG.

Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26.

47.

Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression.

Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF.

PLoS One. 2011;6(10):e26056. doi: 10.1371/journal.pone.0026056. Epub 2011 Oct 6.

48.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Schwager SM, Leis JF, Jelinek DF, Slager SL, Hanson CA.

Leukemia. 2012 Feb;26(2):373-6. doi: 10.1038/leu.2011.211. Epub 2011 Aug 12. No abstract available.

PMID:
21836611
49.

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.

Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay NE, Witzig TE, Weiner GJ.

Leuk Lymphoma. 2012 Feb;53(2):211-7. doi: 10.3109/10428194.2011.608451. Epub 2011 Sep 19.

50.

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD.

Blood. 2011 Sep 8;118(10):2821-6. doi: 10.1182/blood-2011-04-349134. Epub 2011 Jul 15.

Supplemental Content

Support Center